Published in Proc Natl Acad Sci U S A on August 29, 2000
PML targeting eradicates quiescent leukaemia-initiating cells. Nature (2008) 3.75
Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol (2007) 3.03
Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer (2010) 2.66
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest (2001) 2.00
Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med (2001) 1.63
One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett (2013) 1.49
Mzf1 controls cell proliferation and tumorigenesis. Genes Dev (2001) 1.43
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood (2011) 1.41
PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J Exp Med (2004) 1.34
The APL paradigm and the "co-clinical trial" project. Cancer Discov (2011) 1.33
The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev (2009) 1.24
The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol (2012) 1.17
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci (2007) 1.17
Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med (2013) 1.15
Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood (2009) 1.06
Harnessing preclinical mouse models to inform human clinical cancer trials. J Clin Invest (2006) 1.06
The nuclear bodies inside out: PML conquers the cytoplasm. Curr Opin Cell Biol (2011) 1.01
Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies. J Exp Med (2013) 0.95
Animal models in burn research. Cell Mol Life Sci (2014) 0.95
In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemia. J Exp Med (2006) 0.92
Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism. Cancer Chemother Pharmacol (2008) 0.91
A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett (2012) 0.89
Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation. J Clin Invest (2005) 0.89
Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxide. Mol Cell Biochem (2009) 0.88
Berberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide. BMC Cancer (2008) 0.88
Mouse hospital and co-clinical trial project--from bench to bedside. Nat Rev Clin Oncol (2015) 0.86
Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth. Oncotarget (2015) 0.86
Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia. Proc Natl Acad Sci U S A (2002) 0.85
Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis in human hepatoma, breast cancer, and lung cancer cells in vitro. World J Gastroenterol (2005) 0.83
New Strategies to Direct Therapeutic Targeting of PML to Treat Cancers. Front Oncol (2013) 0.81
Establishment of a humanized APL model via the transplantation of PML-RARA-transduced human common myeloid progenitors into immunodeficient mice. PLoS One (2014) 0.78
MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells. Invest New Drugs (2009) 0.78
Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma. Pediatr Blood Cancer (2012) 0.76
Mutations of Chromatin Structure Regulating Genes in Human Malignancies. Curr Protein Pept Sci (2016) 0.76
Targeting of leukemia-initiating cells in acute promyelocytic leukemia. Stem Cell Investig (2015) 0.76
Meta-Analysis of Gene Expression Profiles in Acute Promyelocytic Leukemia Reveals Involved Pathways. Int J Hematol Oncol Stem Cell Res (2017) 0.75
On arsenic trioxide in the clinical treatment of acute promyelocytic leukemia. Leuk Res Rep (2017) 0.75
Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. Onco Targets Ther (2017) 0.75
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature (1998) 18.36
Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res (1998) 8.95
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med (1998) 6.83
The POZ domain: a conserved protein-protein interaction motif. Genes Dev (1994) 5.96
Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 5.63
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 5.30
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood (1997) 4.78
Acute promyelocytic leukemia. N Engl J Med (1993) 4.63
Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood (1999) 4.58
NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood (1991) 4.30
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood (1997) 3.56
Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res (1996) 3.37
Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet (1998) 2.97
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst (1998) 2.75
Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A (1997) 2.47
Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst (1999) 2.41
PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO J (1993) 2.29
Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med (1999) 1.91
Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci U S A (1999) 1.88
Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood (1995) 1.58
Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res (1999) 1.53
Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance. Blood (1999) 1.50
Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood (1998) 1.45
The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood (1996) 1.29
Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood (1998) 1.26
PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol (1999) 1.25
Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood (1998) 1.20
Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood (1999) 1.18
Acute promyelocytic leukemia cases with nonreciprocal PML/RARa or RARa/PML fusion genes. Blood (1995) 1.08
In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. Oncogene (1999) 1.04
Targeting the PML/RAR alpha translocation product triggers apoptosis in promyelocytic leukemia cells. Oncogene (1998) 0.97
Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. Blood (1999) 0.89
Gene rearrangements in the molecular pathogenesis of acute promyelocytic leukemia. J Cell Physiol (1997) 0.85
Pten is essential for embryonic development and tumour suppression. Nat Genet (1998) 13.41
Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell (1991) 9.40
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 8.20
The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature (1999) 7.85
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med (1998) 6.83
The multiple roles of PTEN in tumor suppression. Cell (2000) 6.71
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet (2001) 5.92
The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet (1997) 5.55
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (2000) 4.90
Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol (1999) 4.42
The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene (2008) 4.39
Impaired Fas response and autoimmunity in Pten+/- mice. Science (1999) 4.25
Role of SUMO-1-modified PML in nuclear body formation. Blood (2000) 4.05
Role of PML in cell growth and the retinoic acid pathway. Science (1998) 3.82
The transcriptional role of PML and the nuclear body. Nat Cell Biol (2000) 3.80
PML is essential for multiple apoptotic pathways. Nat Genet (1998) 3.75
Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med (2001) 3.62
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol (2001) 3.24
The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med (1992) 2.99
Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet (1998) 2.97
The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene (1995) 2.80
Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med (1990) 2.76
Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst (1998) 2.64
BCL-6 regulates chemokine gene transcription in macrophages. Nat Immunol (2000) 2.58
Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A (1997) 2.47
Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J (2000) 2.38
The function of PML in p53-dependent apoptosis. Nat Cell Biol (2000) 2.24
Plzf regulates limb and axial skeletal patterning. Nat Genet (2000) 2.14
Acute promyelocytic leukemia: from genetics to treatment. Blood (1994) 2.09
Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest (1991) 2.08
All-trans-retinoic acid: what is it good for? J Clin Oncol (1992) 2.03
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest (2001) 2.00
A role for PML and the nuclear body in genomic stability. Oncogene (1999) 1.97
The theory of APL revisited. Curr Top Microbiol Immunol (2007) 1.96
Transcriptional repression of Stat6-dependent interleukin-4-induced genes by BCL-6: specific regulation of iepsilon transcription and immunoglobulin E switching. Mol Cell Biol (1999) 1.91
Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci U S A (1991) 1.90
Murine embryonic stem cells without pig-a gene activity are competent for hematopoiesis with the PNH phenotype but not for clonal expansion. J Clin Invest (1997) 1.86
Evidence for BLM and Topoisomerase IIIalpha interaction in genomic stability. Hum Mol Genet (2001) 1.85
A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins. Nat Genet (1999) 1.78
p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl). J Exp Med (2001) 1.73
Arsenic trioxide, a therapeutic agent for APL. Oncogene (2001) 1.72
Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood (1997) 1.69
Regulation of apoptosis by PML and the PML-NBs. Oncogene (2008) 1.67
Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ (2009) 1.67
Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med (2001) 1.63
Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene (1992) 1.59
The chromosome make-up of mouse embryonic stem cells is predictive of somatic and germ cell chimaerism. Transgenic Res (1997) 1.54
Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins. J Biol Chem (1998) 1.48
PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. EMBO J (2001) 1.47
Computational method to reduce the search space for directed protein evolution. Proc Natl Acad Sci U S A (2001) 1.47
Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias. J Exp Med (1990) 1.47
Increased sensitivity to complement and a decreased red blood cell life span in mice mosaic for a nonfunctional Piga gene. Blood (1999) 1.46
Two cases of extramedullary acute promyelocytic leukemia. Cytogenetics, molecular biology, and phenotypic and clinical studies. Cancer (1994) 1.45
Mzf1 controls cell proliferation and tumorigenesis. Genes Dev (2001) 1.43
Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. J Exp Med (2000) 1.43
CD2 expression and PML/RAR-alpha transcripts in acute promyelocytic leukemia. Blood (1993) 1.41
Adiabatic shear failure and dynamic stored energy of cold work. Phys Rev Lett (2006) 1.39
Regulation of Pax3 transcriptional activity by SUMO-1-modified PML. Oncogene (2001) 1.35
Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol (1997) 1.34
Two critical hits for promyelocytic leukemia. Mol Cell (2000) 1.33
Rational evolutionary design: the theory of in vitro protein evolution. Adv Protein Chem (2000) 1.29
Role of PML and PML-RARalpha in Mad-mediated transcriptional repression. Mol Cell (2001) 1.29
Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res (1992) 1.26
A family of Shc related proteins with conserved PTB, CH1 and SH2 regions. Oncogene (1996) 1.26
Anomalous photogalvanic effect of circularly polarized light incident on the two-dimensional electron gas in Al{x}Ga{1-x}N/GaN heterostructures at room temperature. Phys Rev Lett (2008) 1.25
Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1992) 1.24
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood (2000) 1.23
Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia (2006) 1.22
Dyskerin expression influences the level of ribosomal RNA pseudo-uridylation and telomerase RNA component in human breast cancer. J Pathol (2006) 1.20
Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood (1998) 1.20
Phosphoinositide 3-kinase-dependent membrane recruitment of p62(dok) is essential for its negative effect on mitogen-activated protein (MAP) kinase activation. J Exp Med (2001) 1.19
Identification of PTEN at the ER and MAMs and its regulation of Ca(2+) signaling and apoptosis in a protein phosphatase-dependent manner. Cell Death Differ (2013) 1.19
Method to enhance growth and sporulation of pelletized biocontrol fungi. Appl Environ Microbiol (1991) 1.15
Realization of extremely broadband quantum-dot superluminescent light-emitting diodes by rapid thermal-annealing process. Opt Lett (2008) 1.14
Role of the promyelocytic leukemia protein PML in the interferon sensitivity of lymphocytic choriomeningitis virus. J Virol (2001) 1.14
The theory of APL. Oncogene (2001) 1.12
Characterization of the PML-RAR alpha chimeric product of the acute promyelocytic leukemia-specific t(15;17) translocation. Cancer Res (1992) 1.11
Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1. Proc Natl Acad Sci U S A (2001) 1.11
FES-Cre targets phosphatidylinositol glycan class A (PIGA) inactivation to hematopoietic stem cells in the bone marrow. J Exp Med (2001) 1.08
Focal adhesion kinase as potential target for cancer therapy (Review). Oncol Rep (2009) 1.08
Methylglyoxal-bis(guanylhydrazone) (Methyl-GAG): current status and future prospects. J Clin Oncol (1983) 1.07
Gossypol: a potential antifertility agent for males. Annu Rev Pharmacol Toxicol (1984) 1.07
The role of PML in the control of apoptotic cell fate: a new key player at ER-mitochondria sites. Cell Death Differ (2011) 1.07
Observation of a charged charmoniumlike structure in e+ e- → π+ π- J/ψ at sqrt[s] = 4.26 GeV. Phys Rev Lett (2013) 1.05
Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol (1986) 1.05
The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. Oncogene (2007) 1.05
Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies, and implications. Blood (1993) 1.04
In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. Oncogene (1999) 1.04